These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27492528)

  • 61. [Prevalence and characteristics of rhinitis in adult asthmatic patients attending allergist, primary care and pulmonologist settings in Spain (AIR study)].
    Castillo JA; Navarro A; Quirce S; Molina J; García-Marcos L; Juliá B; Valero A; Mullol J
    Med Clin (Barc); 2011 Mar; 136(7):284-9. PubMed ID: 21047654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Main Contributory Factors on Asthma Control and Health-Related Quality of Life in Elderly Asthmatics.
    Enríquez-Matas A; Fernández-Rodríguez C; Andrés Esteban EM; Fernández-Crespo J
    J Investig Allergol Clin Immunol; 2020; 30(4):264-271. PubMed ID: 31283523
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
    Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
    Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma.
    Chen H; Blanc PD; Hayden ML; Bleecker ER; Chawla A; Lee JH;
    Value Health; 2008; 11(2):231-9. PubMed ID: 18380635
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Models of care for severe asthma: the role of primary care.
    Chung LP; Johnson P; Summers Q
    Med J Aust; 2018 Jul; 209(S2):S34-S40. PubMed ID: 30453871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The dark side of the moon: severe therapy-resistant asthma in children.
    de Benedictis FM; Carloni I; Bush A
    Monaldi Arch Chest Dis; 2012 Jun; 77(2):83-93. PubMed ID: 23193845
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).
    Schleich F; Brusselle G; Louis R; Vandenplas O; Michils A; Pilette C; Peche R; Manise M; Joos G
    Respir Med; 2014 Dec; 108(12):1723-32. PubMed ID: 25456708
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.
    Baxter-Jones AD; Helms PJ; Russell G; Grant A; Ross S; Cairns JA; Ritchie L; Taylor R; Reid DM; Osman LM; Robins S; Fletcher ME
    Health Technol Assess; 2000; 4(28):1-89. PubMed ID: 11074396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients.
    Jeong SH; Lee H; Carriere KC; Shin SH; Moon SM; Jeong BH; Koh WJ; Park HY
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1857-65. PubMed ID: 27536097
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Real life study of three years omalizumab in patients with difficult-to-control asthma.
    López Tiro JJ; Contreras EA; del Pozo ME; Gómez Vera J; Larenas Linnemann D
    Allergol Immunopathol (Madr); 2015; 43(2):120-6. PubMed ID: 24780091
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
    Gibson PG; Reddel H; McDonald VM; Marks G; Jenkins C; Gillman A; Upham J; Sutherland M; Rimmer J; Thien F; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Robinson P; Wright C; Yozghatlian V; Burgess S; Sivakumaran P; Jaffe A; Bowden J; Wark PA; Yan KY; Kritikos V; Peters M; Hew M; Aminazad A; Bint M; Guo M
    Intern Med J; 2016 Sep; 46(9):1054-62. PubMed ID: 27350385
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predictors of future exacerbation risk in patients with asthma.
    Papaioannou AI; Kostikas K; Bakakos P; Papaporfyriou A; Konstantellou E; Hillas G; Papatheodorou G; Koulouris NG; Papiris S; Loukides S
    Postgrad Med; 2016 Sep; 128(7):687-92. PubMed ID: 27494758
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recent asthma exacerbations: a key predictor of future exacerbations.
    Miller MK; Lee JH; Miller DP; Wenzel SE;
    Respir Med; 2007 Mar; 101(3):481-9. PubMed ID: 16914299
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.
    Mascia K; Haselkorn T; Deniz YM; Miller DP; Bleecker ER; Borish L;
    J Allergy Clin Immunol; 2005 Nov; 116(5):970-5. PubMed ID: 16275362
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Control of asthma in the Maghreb: results of the AIRMAG study.
    Benkheder A; Bouacha H; Nafti S; Taright S; El Ftouh M; Yassine N; Fakhfakh H; Ali-Khoudja M; Texier N; El Hasnaoui A
    Respir Med; 2009 Dec; 103 Suppl 2():S12-20. PubMed ID: 20122624
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Are overweight asthmatics more difficult to control?
    Saint-Pierre P; Bourdin A; Chanez P; Daures JP; Godard P
    Allergy; 2006 Jan; 61(1):79-84. PubMed ID: 16364160
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical experience with omalizumab in a Portuguese severe asthma unit.
    Alfarroba S; Videira W; Galvão-Lucas C; Carvalho F; Bárbara C
    Rev Port Pneumol; 2014; 20(2):78-83. PubMed ID: 24525397
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function.
    Paro-Heitor ML; Bussamra MH; Saraiva-Romanholo BM; Martins MA; Okay TS; Rodrigues JC
    Pediatr Pulmonol; 2008 Feb; 43(2):134-41. PubMed ID: 18085692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.